| Literature DB >> 32272749 |
Andreas Klameth1, Andreas Neubauer1, Christian Keller2, Christian Aepinus2, Ulrich Kaiser3, Jörg Hoffmann1, Cornelia Brendel1.
Abstract
Flow cytometry (FC) facilitates diagnosis of peripheral T-cell non-Hodgkin lymphoma (T-NHL), but overlapping features between reactive and neoplastic T-cell proliferations often hamper a rapid assessment. One hundred forty peripheral blood samples submitted to diagnostic FC for T-cell immunophenotyping were retrospectively analyzed. A T-cell population with a conspicuous aberrant surface epitope expression pattern was observed in 18 cases and diagnostic follow up was performed. The aberrant T-cell population exhibited a low scatter profile, a CD7-negative/low, CD8-low and CD3-positive immunophenotype, and monoclonal T-cell receptor expansion. T-NHL was ruled out by follow up in all cases. Epstein-Barr virus infection was diagnosed in 12 cases, cytomegalovirus infection in three cases; one patient had been vaccinated. The irregular subpopulation disappeared spontaneously within days or weeks. We describe a novel peripheral blood T-cell subpopulation with a low light scatter and CD8-low, CD7-negative/low and CD3-positive marker expression profile, which indicates reactive T-cell expansion in patients who present with peripheral lymphadenopathy and/or B symptoms.Entities:
Keywords: T-cell lymphoma; aberrant CD3; low CD7; negative lymphocytes; positive CD8; viral infection
Year: 2020 PMID: 32272749 PMCID: PMC7235783 DOI: 10.3390/diagnostics10040204
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Patient characteristics.
| Patient (no.) | Age (years) | Sex | % of WBC | % of Lymphocytes | Diagnosis |
|---|---|---|---|---|---|
| 1 | 15 | M | 11 | 16 | EBV |
| 2 | 17 | M | 25 | 33 | EBV |
| 3 | 46 | M | 14 | 19 | EBV |
| 4* | 77 | M | 17 | 28 | Unknown viral infection |
| 5* | 31 | M | 24 | 31 | EBV |
| 6 | 65 | M | 4 | 8 | Unknown viral infection |
| 7 | 22 | F | 29 | 37 | EBV |
| 8 | 71 | F | 16 | 25 | CMV |
| 9 | 20 | M | 21 | 31 | EBV |
| 10 | 59 | F | – | – | EBV |
| 11* | 60 | F | 20 | 37 | EBV |
| 12 | 59 | M | 4 | 5 | CMV |
| 13 | 26 | F | 14 | 31 | EBV |
| 14 | 45 | F | 14 | 22 | CMV |
| 15 | 18 | M | 2 | 2 | EBV |
| 16 | 17 | M | 7 | 12 | EBV |
| 17 | 37 | F | 10 | 24 | MMR |
| 18 | 37 | M | 1 | 1.3 | EBV |
Patient age, sex, percentage of aberrant SSC/FSC-low T-cells in all white blood cells (WBC), and percentage of aberrant T-cells in relation to all lymphocytes are depicted. * Indicates the patient samples on which TCR analysis was performed. Abbreviations: EBV, acute Epstein-Barr virus infection; CMV, Cytomegalovirus; MMR, Measles mumps rubella.
Flow cytometric characteristics of the aberrant T-cell population. Scatter characteristics, expression of CD3, CD8, CD4, CD5, CD2, CD7, HLA-DR, T-cell receptor alpha and beta and CD4/CD8 ratio are depicted for each sample. “+++” indicates strong expression levels, “++” normal expression, “+” weak expression and “-” lack of expression. Abbreviations: n.i., Not investigated.
| Patient (no.) | SSC/FSC | CD3 | CD8 | CD4 | CD5 | CD2 | CD7 | HLA-DR | TCR α/β | CD4/CD8 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Low | ++ | ++ | - | ++ | ++ | - | + | ++ | 0.07 |
| 2 | Low | ++ | + | - | ++ | ++ | - | n.i. | + | 0.18 |
| 3 | Low | + | + | - | + | + | - | + | + | 0.09 |
| 4 | Low | ++ | + | - | + | ++ | - | n.i. | + | 0.4 |
| 5 | Low | ++ | ++ | - | ++ | ++ | - | n.i. | + | 0.1 |
| 6 | Low | ++ | + | - | ++ | ++ | - | n.i. | + | 0.8 |
| 7 | Low | ++ | ++ | - | n.i. | n.i. | n.i. | n.i. | n.i. | 0.49 |
| 8 | Low | ++ | ++ | - | ++ | ++ | - | n.i. | ++ | 0.31 |
| 9 | Low | ++ | ++ | - | +++ | ++ | - | n.i. | + | 0.21 |
| 10 | Low | +++ | ++ | - | ++ | ++ | - | n.i. | +++ | 1.8 |
| 11 | Low | ++ | + | - | + | ++ | - | n.i. | + | 0.32 |
| 12 | Low | +++ | ++ | - | ++ | +++ | - | n.i. | ++ | 0.17 |
| 13 | Low | +++ | ++ | - | ++ | ++ | - | + | + | 0.18 |
| 14 | Low | +++ | ++ | - | ++ | ++ | - | n.i. | ++ | 0.25 |
| 15 | Low | +++ | ++ | - | ++ | +++ | + | n.i. | +++ | 0.04 |
| 16 | Low | +++ | ++ | - | ++ | +++ | - | ++ | n.i. | 0.11 |
| 17 | Low | ++ | + | - | + | + | - | n.i. | + | 0.28 |
| 18 | Low | ++ | ++ | - | + | + | - | n.i. | n.i. | 0.29 |
Figure 1Gating strategy for the characteristic aberrant T-cell population. (A) Forward scatter versus side scatter gating identifies small aberrant cells indicated in red (left) with low CD45 expression (right). (B) The aberrant T-cells are CD3-positive (left). Plotting of CD4 versus CD8 highlights the lower expression of CD8 in these aberrant T-cells (right). (C) Diminished CD2 and CD5 marker expression on the small aberrant T-cell fraction (left); side scatter versus CD7 plotting demonstrates lack of/weak expression of CD7 (right).
Figure 2Clonal V beta T-cell receptor expansion on the aberrant cell population. In each row, gating on lymphocytes and CD3-positive cells (colored black) is shown (left and middle). On the right, analysis of Vß TCR of the CD3-positive cells is depicted. In row C, Vß TCR in Vß20/Vß5.1 versus Vß18/Vß5.1 is shown on the right. Monoclonal expression of Vß18 is clearly visible (colored red).
Figure 3Cell sorting and dead cell exclusion. After dead cell exclusion via DAPI stain, the viable cells were further sorted and analyzed separately for viral infection. Dead cell exclusion is shown in the left plot. Sorting strategy for CD4, CD8-high and CD8-low cells is shown in the right plot.
EBV-PCR analysis of FACS-sorted cell subsets.
| Population | CD8-High | CD4+ | CD8-Low | CD19+ | Granulocytes |
|---|---|---|---|---|---|
| EBV-PCR | negative | negative | positive | positive | negative |
Patient T-cells were sorted for high and low expression of CD8 via flow cytometry. Additional sorting was performed for CD4+ T-cells, CD19+ cells and granulocytes. EBV PCR analysis was positive for T-cells with low CD8 expression but not for T-cells with a regular high CD8 expression level. CD19-expressing B-cells also gave a positive PCR signal for EBV.
Figure 4Time-course of aberrant T-cell clearance. The percentage of SSC/FSC-low aberrant T-cells per total lymphocyte count was determined throughout a follow-up period of several weeks in six patients.